Claudine J. Isaacs
Expertise in
12
conditions

Dr. Claudine J. Isaacs

Hematology Oncology | Oncology
Medstar Medical Group Ii LLC
3800 Reservoir Rd Nw, 
Washington, DC 
33 Years of Experience
Expertise in
12
conditions
Medstar Medical Group Ii LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Claudine Isaacs is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Isaacs has been practicing medicine for over 33 years is highly rated in 12 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 259 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MEDSTAR MEDICAL GROUP II LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Procedure, Other
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Drug, Other
Study Drugs: Alisertib, Fulvestrant
Study Phase: Phase 2
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Study Phase: Phase 2
TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drugs: Talazoparib, Avelumab
Study Phase: Phase 1/Phase 2
A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)
A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)
Enrollment Status: Completed
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Bosutinib, Fulvestrant
Study Phase: Phase 1
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Phase: Phase 1
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
The Genetic Education for Men (GEM) Trial: Web-Based Genetic Education vs. Standard Care in Men From Hereditary Cancer Families
The Genetic Education for Men (GEM) Trial: Web-Based Genetic Education vs. Standard Care in Men From Hereditary Cancer Families
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 20, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 12 Less Clinical Trials

256 Total Publications

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Journal: Nature communications
Published: September 09, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (0.1 miles away)
202-444-3700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Craig Kessler is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Kessler is highly rated in 30 conditions, according to our data. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy. Dr. Kessler is currently accepting new patients.

Expertise in
18
conditions
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology
Expertise in
18
conditions
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (35.5 miles away)
410-328-1230
Languages Spoken:
English, German, Spanish, Yoruba
See accepted insurances
Accepting New Patients

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Expertise in
30
conditions
Dr. Catherine M. Broome
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Catherine M. Broome
Hematology Oncology | Hematology | Oncology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (0.1 miles away)
202-444-3700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Catherine Broome is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Broome is highly rated in 30 conditions, according to our data. Her top areas of expertise are Autoimmune Hemolytic Anemia, Chronic B-Cell Leukemia (CBCL), Thrombocytopenia, Bone Marrow Aspiration, and Splenectomy. Dr. Broome is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Isaacs's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile